A chemotherapy regimen was defined as one or more courses of chemotherapy of a certain type, including conditioning regimens and chemotherapy used for previous and current stem cell mobilization.
A fluoroquinolone regimen was defined as unnecessary if no antimicrobial therapy was indicated for the condition being treated or if the fluoroquinolone component of a regimen was not indicated.
Treatment failure that resulted in a change in regimen was defined as a VL > 5000 copies of HIV RNA/ml, for greater than 6 months, resulting in an immunological decline.
A nonabacavir cART regimen was defined as any regimen combining at least three antiretroviral drugs, none of which were abacavir.
A two-log decrease in the repeat VL measurement 3 months after interventions to support adherence in those suspected of failing a second-line regimen was defined as virological suppression, and these patients were continued on second-line ART.
A patient's initial regimen was defined as the index drug class plus any concomitant use of additional antidiabetic medication classes (alpha-glucosidase inhibitors, amylin analogs, dopamine receptor agonists, GLP-1RAs, insulin, meglitinides, and metformin).
For patients who required an additional rescue dose of canakinumab, the dose regimen was defined as a separate group and the time-to-relapse was calculated from the time of i.v. rescue dose.
All patients included in the study received a loading dose of 25 mg/kg of amikacin based on TBW; this regimen was defined for an expected mean Vd of 0.4 L/kg and a target peak of 64 μg/ml [ 17, 20, 21].
*A regimen was defined as a single drug or combination therapy.
NMA conditioning regimen was defined as TBI 200cGY [ 13].
The short regimen was defined as treatment of MDR TB with duration of <12 months (14 ).
